Skip to main content
Ivosidenib a New Standard of Care for Relapsed or Refractory AML with IDH1 Mutation
Phoebe Starr
Read More
FDA Implements New Steps to Encourage Generic Drug Competition, Expand Patients’ Access to Inexpensive Medicines
Eileen Koutnik-Fotopoulos
Read More
Immunotherapy
NCCN Issues First Guideline for Immunotherapy-Related Adverse Events
Wayne Kuznar
Read More
Immunotherapy
CAR T-Cell Manufacturing Process Depends on Good-Quality T-Cells
Phoebe Starr
Read More
The PARP Inhibitor Rucaparib in the Maintenance Therapy of Recurrent Ovarian Carcinoma: Highlights from the ARIEL3 Clinical Trial
Read More
PARP Inhibitors
An Assessment of PARP Inhibitors in the Treatment of Recurrent Ovarian Cancer
Penny Daugherty, RN, MS, OCN, ONN-CG
Read More
PARP Inhibitors
PARP Inhibitors for Maintenance Therapy in Recurrent Platinum-Sensitive Ovarian Cancer
Ambar Khan, PharmD, BCOP
Read More
FDA Updates
A Dynamic FDA Has Led to More Rapid Cancer Drug Development
Wayne Kuznar
Read More
Original Research
Assessing Basic Cytotoxic Drug Levels in Hospital Pharmacies and the Efficacy of a Closed-System Drug-Transfer Device to Reduce Contamination
Ákos Juhász, PharmD, Attila Szűcs, PharmD, András Süle, PharmD, PhD
Read More
Original Research
Evaluation of the Role of Clinical Pharmacists in the Review and Approval of Off-Label Oncology Treatment Requests
Mark L. Zangardi, PharmD, BCOP, E. Bridget Kim, PharmD, BCPS, BCOP, Gayle C. Blouin, PharmD, BCOP
Read More
Page 156 of 196
Results 1551 - 1560 of 1954